Drug package representative plan (oral liquid quantitative administration device)

1. Meets the reporting requirements of China, the US, and Europe;
2. Complies with the relevant requirements in the "Guidelines for Pharmaceutical Development of Pediatric Medicines (Chemical Drugs) (Trial)" issued by CDE in December 2020;
3. No intellectual property concerns;
4. Residual volume ≤ 0.7ml;
5. Professional team;